Astellas Pharma revenue and financials
¥2,255.50Change from previous close: +0.53%Absolute change: +¥12.00
In the fiscal year ended March 2026, Astellas Pharma reported revenue of ¥2.14T (+11.87% year over year). Net income was ¥291.54B, a net margin of 13.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +11.87%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +474.49%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 13.6%
- FY to Mar 2025: 2.7%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 |
|---|---|---|---|---|
| Total assets | 3,567,042 | 3,339,544 | 3,569,603 | 2,456,518 |
| Current assets | 1,421,923 | 1,201,349 | 1,194,730 | 1,049,954 |
| Cash and equivalents | 281,605 | 188,372 | 335,687 | 376,840 |
| Short-term investments | 9,572 | 29,941 | 28,784 | 19,784 |
| Inventory | 331,014 | 297,261 | 248,738 | 174,386 |
| Net property, plant and equipment | 358,424 | 328,921 | 293,742 | 286,459 |
| Goodwill | 441,175 | 415,207 | 418,694 | 328,411 |
| Other intangible assets | 996,932 | 1,123,714 | 1,453,824 | 562,496 |
| Long-term investments | 20,297 | 18,989 | 15,684 | 12,689 |
| Current liabilities | 1,218,401 | 1,061,610 | 1,285,725 | 726,034 |
| Accounts payable | 199,752 | 187,840 | 185,193 | 140,236 |
| Long-term debt | 320,000 | 564,893 | 447,738 | 50,000 |
| Total debt | 565,952 | 831,426 | 920,016 | 125,000 |
| Total liabilities | 1,736,158 | 1,826,289 | 1,973,615 | 948,564 |
| Total equity (incl. minority) | 1,830,884 | 1,513,255 | 1,595,988 | 1,507,954 |
| Retained earnings | 902,836 | 740,939 | 809,400 | 908,158 |
| Minority interest | 1,840 | 0.0 | — | — |